Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient
Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-ol...
Saved in:
| Main Authors: | Kim Abbegail Tan Aldecoa, Chef Stan L. Macaraeg, Akash Dadlani, Sri Yadlapalli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2023/1691996 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
REAL-WORLD ANALYSIS OF PATIENTS WITH CLL TREATED WITH IBRUTINIB: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN REGISTRY OF CLL
by: V Pfister, et al.
Published: (2024-10-01) -
Spontaneous hyphema in juvenile idiopathic arthritis uveitis
by: Figen Bezci Aygun, et al.
Published: (2023-02-01) -
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
by: Mazyar Shadman, et al.
Published: (2025-08-01) -
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL
by: John N. Allan, et al.
Published: (2025-08-01) -
Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials
by: Ahmad Y. Abuhelwa, et al.
Published: (2025-07-01)